


**Supplementary Figure 1 Histopathological features indicating the aggressive biology of PCC-NOS compared to SRCC** A: PCC-NOS localized to the invasive front compared to centrally located SRCC in EGC; B: Prominent desmoplastic reaction around PCC-NOS



**Supplementary Figure 2 ROC curves for predicting lymph node metastasis in EGC.**

A: ROC curve for the baseline model including tumor size and ulceration as variables (AUC = 0.714); B: ROC curve for the model incorporating tumor size, ulceration, and SRCC proportion as variables (AUC = 0.7297). ROC: Receiver operating characteristics; AUC: Area under the curve.

**Supplementary Table 1 SRCC rate according to AJCC pT stage, mean  $\pm$  SD**

	Total (N=1066)	T1a (N=435)	T1b (N=214)	T2 (N=86)	T3 (N=97)	T4a (N=205)	T4b (N=29)	<sup>1</sup> P value
SRCC rate (%) ( <sup>b</sup> )	58.22 $\pm$ 34.03	79.48 $\pm$ 25.27	54.35 $\pm$ 29.71	46.4 32.97	$\pm$ 39.07 29.26	$\pm$ 34.61 $\pm$ 30.84	33.97 $\pm$ 27	<0.001

<sup>1</sup>P value was calculated by ANOVA test.

**Supplementary Table 2 SRCC rate according to pN stage**

SRCC rate according to AJCC pN stage							
	Total (N=1066)	N0 (N=764)	N1 (N=62)	N2 (N=74)	N3a (N=65)	N3b (N=101)	P value
SRCC rate (%) (mean $\pm$ SD)	58.22 $\pm$ 34.03	66.37 $\pm$ 31.67	43.31 $\pm$ 32.84	38.11 $\pm$ 31.4	34.54 $\pm$ 31.23	35.69 $\pm$ 29.24	<0.001
SRCC rate according to Japanese pN stage							

	Total	N0	1	2	3	<i>P</i> value	Total
	(N=1045)	(N=756)	(N=143)	(N=132)	(N=14)		
SRCC rate (%) (mean± SD)	58.22 ± 34.03	66.49 ± 31.57	36.96 ± 31.53	37.95 ± 29.83	41.79 ± 34.56	<0.001	58.22 ± 34.03

*P* value was calculated by ANOVA test.

**Supplementary Table 3 SRCC rate according to AJCC pM stage**

	Total	M0	M1	<i>P</i>
	(N=1066)	(N=1039)	(N=27)	value
SRCC rate (%) (mean±SD <sup>b</sup> )	58.22 ± 34.03	58.81 ± 33.87	35.56 ± 32.94	0.0012

*P* value was calculated by t-test.

**Supplementary Table 4 SRCC rates according to the lymph nodal metastasis in EGC**

<b>Lymph nodal metastasis</b>	<b>Total (N=649)</b>	<b>absent (N=613)</b>	<b>present (N=36)</b>	<b><i>P</i> value</b>
SRCC rate (%) (mean±SD)	71.19 ± 29.29	71.93 ± 28.85	58.61 ± 34.01	0.0269

*P* value was calculated by t-test.

**Supplementary Table 5 SRCC rates according to ulcer presence in EGC**

	<b>Total (N=649)</b>	<b>0 (N=516)</b>	<b>1 (N=133)</b>	<b><i>P</i> value</b>
SRCC rate (%) (mean±SD)	71.19 ± 29.29	73.25 ± 28.58	63.23 ± 30.71	<0.001

*P* value was calculated by t-test.

**Supplementary Table 6 SRCC rates according to tumor size in EGC**

	<b>Total</b> <b>(N=1066)</b>	<b>≤2cm</b> <b>(N=392)</b>	<b>&gt;2cm to ≤4cm</b> <b>(N=342)</b>	<b>&gt;4cm</b> <b>(N=332)</b>	<b>P value</b>
SRCC rate (%) (mean±SD)	58.22 ± 34.03	71.59 ± 30.27	58.61 ± 32.93	42.03 ± 32.42	<0.001

*P* value was calculated by ANOVA test.

**Supplementary Table 7 Submucosal invasion depth according to SRCC group in pT1b EGC**

	<b>Total</b> <b>(N=214)</b>	<b>Gr 1</b> <b>(N=10)</b>	<b>Gr 2</b> <b>(N=79)</b>	<b>Gr 3</b> <b>(N=93)</b>	<b>Gr 4</b> <b>(N=32)</b>	<b>P value</b>
Submucosal invasion depth (μm) (mean±SD)	1479.18 ± 1079.85	1760 ± 836.93	1747.47 ± 1052.41	1374.41 ± 1005.03	1033.59 ± 1255.98	0.0217

*P* value was calculated by ANOVA test.

**Supplementary Table 8 Differences of SRCC rates according to submucosal invasion level.**

	<b>Total</b> <b>(N=214)</b>	<b>sm1</b> <b>(N=41)</b>	<b>sm2</b> <b>(N=173)</b>	<b>P value</b>

SRCC rates (%)	54.35 ± 29.71	73.66 ± 22.72	49.77 ± 29.37	<0.001
(mean±SD)				

---

*P* value was calculated by t-test.